Seyed Danial Alizadeh

Dr. Seyed Danial Alizadeh

Faculty of Medicine, Kerman University of Medical Sciences, Kermān, Iran
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MFMohsen Karami Fath
Mohsen Karami Fath
KBKimiya Babakhaniyan
Kimiya Babakhaniyan
MAMehran Anjomrooz
Mehran Anjomrooz
MJMohammadrasoul Jalalifar
Mohammadrasoul Jalalifar
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
ZPzahra payandeh
zahra payandeh
Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations.

1 January 2024 in Acute Medicine & Surgery
Verified
Journal Article
Open access
MRMohammad Rezaei Zadeh Rukerf
Mohammad Rezaei Zadeh Rukerf
LELida Erfaniparsa
Lida Erfaniparsa
MMMitra Movahedi
Mitra Movahedi
HMHanieh Mirkamali
Hanieh Mirkamali
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
AMAmirhossein Mirafzal
Amirhossein Mirafzal
Aim: Femoral fractures are one of the most debilitating injuries presenting to the emergency departments (EDs). The pain caused by these fractures is typically managed with opioids and adjunctive regional analgesia. These approaches are often associated with adverse side effects. Thus, appropriate alternative methods should be thoroughly investigated. To evaluate ultrasound‐guided femoral nerve block (FNB) with ultrasound‐guided fascia iliaca compartment block (FICB) in femoral fractures, to determine which provides better analgesia and less opioid requirement.Methods: This study was a randomized clinical trial performed on adult patients presenting to the ED within 3 h of isolated femoral fracture with initial numerical pain rating scale (NRS‐0) score of more than 5. The patients were randomized to receive FNB or FICB. The outcomes were block success rates, pain at 20 (NRS‐20) and 60 (NRS‐60) min after the end of the procedures, as well as the number and total dose of fentanyl administration during ED stay.Results: Eighty‐seven patients were recruited (40 FNB and 47 FICB). Success rates were 82.5% in FNB and 83.0% in FICB group, with no significant difference between the groups. NRS‐20, NRS‐60, the number of patients who received supplemental fentanyl, and the total dose of administered fentanyl were significantly lower following FNB. However, the length of the procedure was significantly lower in the FICB group.Conclusion: Both FNB and FICB are effective in pain reduction for fractures of femur, but FNB provides more pain relief and less need for supplemental fentanyl.

4 November 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
HMHanieh Mirkamali
Hanieh Mirkamali
MNMohsen Nakhaie
Mohsen Nakhaie
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
GATA2 deficiency is an autosomal dominant disease that manifests with a range of clinical symptoms, including increased susceptibility to viral, bacterial, and fungal infections. Furthermore, the increased susceptibility to infections in GATA2 deficiency can trigger hemophagocytic lymphohistiocytosis (HLH) in these patients. Our systematic review evaluates reported cases of GATA2 deficiency and HLH in the literature. A systematic review of case reports was conducted following PRISMA 2020 guidelines, encompassing studies retrieved from Ovid MEDLINE ALL, Embase via Ovid SP, Scopus, Web of Science, and Google Scholar from inception until June 14, 2024. This review included studies reporting patients diagnosed with GATA2 deficiency or having a documented history of the condition, who subsequently developed or were concurrently diagnosed with HLH. Various study types were considered, such as case reports, case series, letters to editors, original articles, correspondences, and commentaries, without any restrictions on language. In our systematic review, 15 studies from 2016 to 2024 were analyzed, encompassing 23 patients with GATA2 deficiency and HLH. the mean (SD) age of patients was 23.48 (10.54) years, ranging from 7 to 57 years. These patients exhibited diverse genetic mutations and a spectrum of infections, particularly Mycobacterium avium (M. avium), Mycobacterium kansasii (M. kansasii), Epstein-Barr virus (EBV), cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), and influenza A, often leading to HLH. Family histories of GATA2-deficient patients with HLH occasionally reveal confirmed GATA2 mutations or suspicious cases among first-degree relatives. Hematopoietic stem cell transplantation (HSCT) was performed in 8 patients with GATA2 deficiency and HLH. Among them, 6 patients survived post-therapy, while 2 patients died following HSCT. Currently, 1 patient is being considered for HSCT. The overall mortality rate among GATA2 deficiency patients who experienced HLH was 39.13%. This systematic review highlights GATA2 deficiency’s association with diverse infections triggering HLH, emphasizing early infection management to mitigate mortality risks. This comprehensive analysis contributes to scientific knowledge, offering important insights for clinicians and researchers in diagnosing and managing this rare condition.

6 March 2024 in Spinal Cord
Verified
Journal Article
Open access
PDF file
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
MJMohammad-Rasoul Jalalifar
Mohammad-Rasoul Jalalifar
ZGZahra Ghodsi
Zahra Ghodsi
MSMohsen Sadeghi-Naini
Mohsen Sadeghi-Naini
HMHamid Malekzadeh
Hamid Malekzadeh
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Study design A Systematic Review Objectives To determine the therapeutic efficacy of in vivo reprogramming of astrocytes into neuronal-like cells in animal models of spinal cord injury (SCI). Methods PRISMA 2020 guidelines were utilized, and search engines Medline, Web of Science, Scopus, and Embase until June 2023 were used. Studies that examined the effects of converting astrocytes into neuron-like cells with any vector in all animal models were included, while conversion from other cells except for spinal astrocytes, chemical mechanisms to provide SCI models, brain injury population, and conversion without in-vivo experience were excluded. The risk of bias was calculated independently. Results 5302 manuscripts were initially identified and after eligibility assessment, 43 studies were included for full-text analysis. After final analysis, 13 manuscripts were included. All were graded as high-quality assessments. The transduction factors Sox2, Oct4, Klf4, fibroblast growth factor 4 (Fgf4) antibody, neurogenic differentiation 1 (Neurod1), zinc finger protein 521 (Zfp521), ginsenoside Rg1, and small molecules (LDN193189, CHIR99021, and DAPT) could effectively reprogramme astrocytes into neuron-like cells. The process was enhanced by p21-p53, or Notch signaling knockout, valproic acid, or chondroitin sulfate proteoglycan inhibitors. The type of mature neurons was both excitatory and inhibitory. Conclusion Astrocyte reprogramming to neuronal-like cells in an animal model after SCI appears promising. The molecular and functional improvements after astrocyte reprogramming were demonstrated in vivo, and further investigation is required in this field.

1 August 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
HMHanieh Mirkamali
Hanieh Mirkamali
SASeyed Danial Alizadeh
Seyed Danial Alizadeh

4 December 2024 in Global Spine Journal
Verified
Journal Article
Open access
MHMarjan Hesari
Marjan Hesari
SASeyed Danial Alizadeh
Seyed Danial Alizadeh
HMHamid Malekzadeh
Hamid Malekzadeh
RTReza Tabrizi
Reza Tabrizi
MJMohammad-Rasoul Jalalifar
Mohammad-Rasoul Jalalifar
VRVafa Rahimi-Movaghar
Vafa Rahimi-Movaghar
Study Design: Systematic Review and Meta-Analyses. Objective: To assess the 30- and 90-day readmission rates after a traumatic spinal cord injury (SCI). Methods: A systematic search of MEDLINE and Embase was performed. The period was from inception to June 2022, with no language restrictions. All studies investigating the 30- and/or 90-day readmission rate following traumatic SCI were included. A random-effects model to combine effect sizes in our meta-analysis was applied. Results: Seven out of 2959 reports met eligibility. The mean age of the patients was 50.2 ± 19.9, with a male-to-female ratio of 2.4:1. The most common traumatic SCI was cervical injury (55.3%). The meta-analysis model revealed a 30-day readmission rate of 14.2% after traumatic SCI, with heterogeneity in the studies. The 90-day readmission rate was 35.7%, with homogeneity in the studies. The meta-regression analysis found significant positive associations between cervical and thoracolumbar injuries and patient age and the 30-day readmission rate, while male sex demonstrated a negative association with the 30-day readmission rate. The 30-day readmission rate following index admission was 13.1% and the 30-day readmission rate after rehabilitation facilities was 15.8%. The study found that the 30-day readmission rate in the USA was 14.0%. Conclusions: There is no doubt that readmission is an adverse health outcome. The outcome is also complex and multifaceted, which makes it difficult to predict. Injury level is 1 of the predictors that affect readmission, making it essential to consider factors during discharge planning for high-risk people to reduce 30-day readmission rates.